ChemoCentryx traded at $25.33 this Wednesday July 6th, decreasing $1.52 or 5.66 percent since the previous trading session. Looking back, over the last four weeks, ChemoCentryx lost 0.56 percent. Over the last 12 months, its price rose by 75.05 percent. Looking ahead, we forecast ChemoCentryx to be priced at 26.03 by the end of this quarter and at 23.98 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,932.00 70.00 1.81% 7.73%
AbbVie 151.15 -1.38 -0.90% 29.46%
Alnylam Pharmaceuticals 150.00 -0.73 -0.48% -13.09%
Amgen 246.23 0.98 0.40% 0.80%
AstraZeneca 11,044.00 66.00 0.60% 28.58%
Bayer 56.77 0.58 1.03% 12.19%
Biogen 217.98 2.00 0.93% -40.93%
BioMarin Pharmaceutical 86.41 0.05 0.06% 4.06%
Bristol-Myers Squibb 75.87 -0.35 -0.46% 13.77%
ChemoCentryx 25.33 -1.52 -5.66% 75.05%
GlaxoSmithKline 1,791.80 1.60 0.09% 25.65%
Glaxosmithkline 43.11 -0.19 -0.44% 7.13%
Incyte Corp 80.58 0.86 1.08% -1.89%
J&J 178.44 0.14 0.08% 5.54%
MacroGenics 3.50 0.08 2.34% -87.47%
Merck & Co 93.20 0.07 0.08% 19.30%
Mirati Therapeutics 68.81 -1.02 -1.46% -56.71%
Novartis 81.90 0.68 0.84% -2.63%
Omeros 3.34 -0.24 -6.70% -77.20%
Pfizer 53.29 0.54 1.02% 35.77%
Roche Holding 326.20 2.85 0.88% -7.84%
Sanofi 98.92 1.02 1.04% 15.32%
Sarepta Therapeutics 77.78 1.81 2.38% 8.04%
Teva Pharmaceutical Industries Ltd 2,656.00 0 0% -14.29%
UCB 84.64 -0.66 -0.77% -5.58%

Indexes Price Day Year
USND 11501 139.15 1.22% -21.01%
US2000 1759 31.32 1.81% -21.19%

ChemoCentryx
ChemoCentryx, Inc. is a biopharmaceutical company that focuses on the development and commercialization of medications targeting inflammatory disorders, autoimmune diseases and cancer. Its drug candidates are designed to selectively block a specific chemoattractant receptor, leaving the rest of the immune system intact. The Company's lead drug candidate Avacopan is a potential first-in-class, an orally-administered molecule that targeted mode of action in the treatment of antineutrophil cytoplasmic antibodies (ANCA) vasculitis and other complement-driven autoimmune and inflammatory diseases. The Company is also developing Avacopan for the treatment of severe (Hurley stage III) hidradenitis suppurativa (HS). Its CCX559 is an orally administered inhibitor for programmed death protein one/programmed death-ligand 1 (PD-1/PD-L1), which are developing for the treatment of various cancers.